Get started
Author

Olivia Triplett

ORCID: 0000-0003-2503-1121
Observed ORCID: 0000-0003-2503-1121
OpenAlex ID: A5040566254
Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
2019 · César Serrano, Alessandro Leal, et al. · Clinical Cancer Research · 58
FLN ‐1/filamin is required to anchor the actomyosin cytoskeleton and for global organization of sub‐cellular organelles in a contractile tissue
2020 · Charlotte A. Kelley, Olivia Triplett, et al. · Cytoskeleton · 12
PDF
Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
2018 · Cesar Serrano, Alessandro Leal, et al. · Journal of Clinical Oncology · 3
Supplementary Methods from Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
2023 · César Serrano, Alessandro Leal, et al.
Supplementary Table S1 from Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
2023 · César Serrano, Alessandro Leal, et al.
Supplementary Figure S1 from Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
2023 · César Serrano, Alessandro Leal, et al.
Supplementary Table S3 from Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
2023 · César Serrano, Alessandro Leal, et al.
Supplementary Table S2 from Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
2023 · César Serrano, Alessandro Leal, et al.
Data from Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
2023 · César Serrano, Alessandro Leal, et al.
Works count: 9
Citation count: 73
H-index: 3
I10-index: 2
Year
Topic
Type